Safety and Efficacy of Inebilizumab for Neuromyelitis Optica Spectrum Disorder
End-of-Study Results from N-MOmentum Trial
In a recent study published in Lancet Neurology, the safety and efficacy of inebilizumab for treating neuromyelitis optica spectrum disorder were investigated. The study included both the randomised controlled period and the open-label extension period.
Key Findings
- 225 participants received inebilizumab, with 208 being AQP4-IgG seropositive.
- Over a 4-year period, 63 adjudicated neuromyelitis optica spectrum disorder attacks occurred in 47 participants, with 40 attacks occurring in the first year.
- Annualised attack rates decreased year-on-year, and most participants who had an attack while receiving inebilizumab were subsequently attack-free at the end of 4 years.
- Overall, 92% of participants who received inebilizumab experienced at least one treatment-emergent adverse event, with urinary tract infection, nasopharyngitis, and arthralgia being the most frequent.
Implications
The end-of-study analysis showed sustained clinical benefits of long-term inebilizumab treatment for individuals with neuromyelitis optica spectrum disorder. This supports the role of inebilizumab as a CD19+ B-cell-depleting therapy in this disorder.
For more information about how our AI-driven platform, DocSym, can help consolidate clinical knowledge and streamline healthcare operations, visit aidevmd.com.
